Navigation Links
Pros, cons of drug proven to prevent prostate cancer should be considered, researchers recommend

DALLAS Jan. 21, 2008 Findings by UT Southwestern Medical Center researchers encourage men to weigh both the potential benefits and side effects of the drug finasteride before taking it to prevent prostate cancer.

In todays online issue of Cancer, UT Southwestern doctors analyzed data gathered by the National Cancer Institutes Prostate Cancer Prevention Trial, or PCPT. The trial, which began in October 1993, was designed to test whether finasteride could prevent prostate cancer in men 55 years of age and older. It was stopped early in June 2003 when an analysis showed that finasteride reduced the risk of developing prostate cancer by 25 percent.

UT Southwesterns analysis of the PCPT data indicates that cost effectiveness and quality of life issues associated with taking the drug are not clear cut, said Dr. Yair Lotan, assistant professor of urology and the Cancer studys senior author. The PCPT data show that in addition to preventing prostate cancer, finasteride also reduces urinary-tract symptoms associated with benign prostatic hyperplasia. It also decreased sexual desire and caused impotence in 5 percent of the trial participants. Some PCPT participants who did develop prostate cancer also had high-grade tumors, although there is ongoing debate whether this result might have been due to sampling bias.

Finasteride is currently the only drug that has been shown to prevent prostate cancer in a large randomized trial but is used for this purpose in very few men, Dr. Lotan said. A large number of patients are currently taking over-the-counter supplements to prevent prostate cancer, even though there is no scientific evidence to support these products claims. Its important for patients to be aware of this scientific trial and to ask their doctors if finasteride could benefit them.

In light of all these pros and cons, Dr. Lotan said physicians and patients need to work together closely to weigh how finasteride could affect quality of life on a case-by-case basis.

With the exception of skin cancer, prostate cancer is the most common cancer in American men, Dr. Lotan said. Men who are at low risk for prostate cancer might view taking finasteride as not very cost effective when considering its impact on their quality of life. On the other hand, patients at high risk might see it as cost effective because it lessens their chances of developing prostate cancer.

Because there is some complexity to the PCPT I think doctors hesitate to discuss its results. While Im not advocating for the drug, I think physicians should mention finasteride, especially when their patients are asking questions about ways to prevent prostate cancer. Patients should understand and be aware of the proven science thats out there.


Contact: Erin Prather Stafford
UT Southwestern Medical Center

Related medicine news :

1. FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales
2. Many Osteoporosis Medications Prevent Fractures, But None Is Proven Best
3. New Booklet Reveals 12 Proven Methods for Stopping MRSA from Infecting Your Feet and Your Familys Feet
4. Gildas Club Worldwide is a Proven Partner in Quality Cancer Care
5. Infliximab scheduled treatment has proven to be an effective strategy in IBD patients
6. Smoked cannabis proven effective in treating neuropathic pain
7. Benefit of exenatide has not yet been proven
8. Proven Nutrition Provides Energy and Hope to Cancer Fighters
9. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
10. European Summit on Cardiovascular Disease Prevention
11. One-third of stunting and a quarter of deaths among under 3s in poor countries could be prevented
Post Your Comments:
Related Image:
Pros, cons of drug proven to prevent prostate cancer should be considered, researchers recommend
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology: